<DOC>
	<DOC>NCT01694693</DOC>
	<brief_summary>Database analysis: - To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA) - To describe joint population of Orencia - To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria - To describe therapeutic strategies and use of health services</brief_summary>
	<brief_title>Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study</brief_title>
	<detailed_description>- Observational Model: Historic cohort generated from Société Française de Rhumatologie's (SFR) Orencia and Rheumatoid Arthritis (ORA) registry - Sampling Method: all physicians and sites taking in charge RA patients received an invitation mailing to participate to ORA - Minimum Age: 18 years old at Orencia initiation</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Adult outpatients, male or female aged ≥ 18 years old Diagnosed with a rheumatoid arthritis according to ACR criteria Treated with Orencia according to usual practice conditions from June 1st 2007 Agreeing to participate Patients treated by Orencia in the context of clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>